drugset
Drugs / AlloJoin®
last change Jul 2023 re-read 3 minutes ago

AlloJoin®

Cell therapy

Developed for
osteoarthritis, knee
Investigated by
China-Japan Friendship Hospital · Huashan Hospital · RenJi Hospital · Second Affiliated Hospital, School of Medicine, Zhejiang University · Shanghai 6th People's Hospital · Shanghai AbelZeta Ltd.
+2 more · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Trials 1

today NCT04208646 · Ph 2
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT04208646 May 2020 → Jun 2021 osteoarthritis, knee Shanghai AbelZeta Ltd. Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as AlloJoin “A Multicenter, Randomized, Double-blind, Controlled Phase II Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells (AlloJoin®) for the Treatment of Knee Osteoarthritis” NCT04208646 ↗
Modality Cell therapy “Evaluate the efficacy and safety of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy” NCT04208646 ↗
Route Other “administrated for intra- articular use” NCT04208646 ↗